Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEPADINA AND SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tepadin A (thiotepa) is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death. It is cell cycle phase-nonspecific.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of adenocarcinoma of the breast,Treatment of adenocarcinoma of the ovary,Palliative treatment of superficial papillary carcinoma of the urinary bladder,Conditioning regimen prior to allogeneic or autologous hematopoietic progenitor cell transplantation (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
6.25 mg/m2 (based on ideal body weight) intravenously over 2 hours every 6 hours for 16 doses (total dose 100 mg/m2) as part of conditioning regimen prior to hematopoietic stem cell transplantation.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life: 1.5–3.5 hours; clinically, the short half-life allows high-intensity dosing with stem cell support
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Primarily metabolized by cytochrome P450 enzymes, including CYP2B6 and CYP3A4, via oxidative desulfuration to active metabolites (e.g., tepa). Also undergoes glutathione conjugation.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily renal; approximately 60-70% of the dose is excreted unchanged in urine within 24 hours; minor fecal elimination (<10%)
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Minimal (<10%); primarily albumin
Low protein binding; 0–11% bound, primarily to albumin.
0.3–0.5 L/kg; indicates limited extravascular distribution
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral: approximately 75% (variable, 30-100%); intravenous: 100%
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific dose adjustments are provided for renal impairment. Use with caution in patients with renal impairment due to potential for nephrotoxicity from the drug or its metabolites; monitor renal function closely.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustments are provided for hepatic impairment based on Child-Pugh score. Use with caution in patients with hepatic impairment; monitor liver function tests closely.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Children and adolescents: Same dose as adults (6.25 mg/m2 intravenously over 2 hours every 6 hours for 16 doses), based on ideal body weight. Safety and efficacy in neonates and infants have not been established.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No specific dose adjustments recommended for elderly patients. Use with caution due to higher likelihood of decreased renal and hepatic function, and monitor for increased toxicity.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
WARNING: THIOTEPA IS HIGHLY TOXIC TO BONE MARROW. SEVERE MYELOSUPPRESSION, INCLUDING DEATH, MAY OCCUR. THIOTEPA IS CARCINOGENIC AND MUTAGENIC. IT SHOULD BE ADMINISTERED ONLY BY PHYSICIANS EXPERIENCED IN CANCER CHEMOTHERAPY.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Bone marrow suppression: Monitor blood counts frequently; dose adjustments may be necessary.,Carcinogenicity: Long-term use increases risk of secondary malignancies (e.g., myelodysplastic syndrome, acute leukemia).,Mutagenicity: Can cause chromosomal damage; use contraception during therapy.,Renal and hepatic impairment: Dose adjustment may be needed.,Hemorrhagic cystitis: Adequate hydration and frequent voiding recommended; monitor for hematuria.,Embryo-fetal toxicity: Can cause fetal harm; avoid pregnancy.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to thiotepa or any component of the formulation,Severe bone marrow depression (e.g., leukopenia, thrombocytopenia)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice due to potential CYP3A4 interaction. Advise small, frequent meals to manage nausea.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
TEPADINA is a known teratogen in animals and is presumed to cause fetal harm when administered to pregnant women. Based on its mechanism of action as an alkylating agent, there is a high risk of teratogenicity, including congenital malformations and fetal demise, particularly during the first trimester. In the second and third trimesters, exposure may lead to fetal growth restriction, myelosuppression, or long-term developmental effects.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
There are no data on the presence of TEPADINA in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, including myelosuppression and carcinogenicity, breastfeeding should be discontinued during treatment and for at least 2 weeks after the last dose.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No specific pharmacokinetic data are available for dosing adjustments in pregnancy. However, due to physiological changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism), careful monitoring for toxicity and efficacy is warranted. No standard dose adjustment is recommended; dosing should be based on therapeutic drug monitoring if available and clinical response.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
TEPADINA AND SODIUM CHLORIDE is used as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT). Administer via intravenous infusion over 1-2 hours. Monitor for infusion reactions (bronchospasm, urticaria) and have resuscitation equipment available. Pre-medicate with anticonvulsants (e.g., phenytoin) to prevent seizure due to CNS toxicity. Observe for hepatotoxicity, especially veno-occlusive disease (VOD), and consider defibrotide prophylaxis. Adjust dose for renal impairment (Cr Cl < 60 m L/min). Use with caution in patients with pre-existing hepatic dysfunction.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is used to prepare your body for a stem cell transplant.,You will receive this drug intravenously (through a vein) in the hospital.,Common side effects include nausea, vomiting, diarrhea, and mouth sores.,You may experience temporary hair loss and skin rash.,Report any signs of infection (fever, chills), bleeding, or unusual bruising immediately.,Avoid driving or operating machinery if you feel dizzy or sleepy.,Do not receive live vaccines during treatment.,Use effective contraception during and for at least 6 months after treatment.,Drink plenty of fluids unless advised otherwise.,Inform your doctor if you have liver or kidney disease.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEPADINA AND SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
TEPADINA AND SODIUM CHLORIDE is a Electrolyte that works by Tepadin A (thiotepa) is an alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death. It is cell cycle phase-nonspecific.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEPADINA AND SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEPADINA AND SODIUM CHLORIDE is: 6.25 mg/m2 (based on ideal body weight) intravenously over 2 hours every 6 hours for 16 doses (total dose 100 mg/m2) as part of conditioning regimen prior to hematopoietic stem cell transplantation.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TEPADINA AND SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TEPADINA AND SODIUM CHLORIDE is classified as Category A/B. TEPADINA is a known teratogen in animals and is presumed to cause fetal harm when administered to pregnant women. Based on its mechanism of action as an alkylating agent, there is . AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.